Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

18,003 recalls, newest first

Class II · Moderate risk

Pyridoxine HCL

Lack of Assurance of Sterility: Lack of sterility assurance in compounded aseptically filled injectable products.

Terminated Sterility / contamination John W Hollis Inc D-1405-2014
Class II · Moderate risk

Lipotropic Gold

Lack of Assurance of Sterility: Lack of sterility assurance in compounded aseptically filled injectable products.

Terminated Sterility / contamination John W Hollis Inc D-1404-2014
Class II · Moderate risk

Papaverine HCl 30 mg

Lack of Assurance of Sterility: Lack of sterility assurance in compounded aseptically filled injectable products.

Terminated Sterility / contamination John W Hollis Inc D-1403-2014
Class II · Moderate risk

Papaverine HCl 30 mg

Lack of Assurance of Sterility: Lack of sterility assurance in compounded aseptically filled injectable products.

Terminated Sterility / contamination John W Hollis Inc D-1402-2014
Class II · Moderate risk

Papaverine HCl 30 mg

Lack of Assurance of Sterility: Lack of sterility assurance in compounded aseptically filled injectable products.

Terminated Sterility / contamination John W Hollis Inc D-1401-2014
Class II · Moderate risk

Papaverine HCl 30 mg

Lack of Assurance of Sterility: Lack of sterility assurance in compounded aseptically filled injectable products.

Terminated Sterility / contamination John W Hollis Inc D-1400-2014
Class II · Moderate risk

Papaverine HCl 30 mg

Lack of Assurance of Sterility: Lack of sterility assurance in compounded aseptically filled injectable products.

Terminated Sterility / contamination John W Hollis Inc D-1399-2014
Class II · Moderate risk

Papaverine HCl 30 mg

Lack of Assurance of Sterility: Lack of sterility assurance in compounded aseptically filled injectable products.

Terminated Sterility / contamination John W Hollis Inc D-1397-2014
Class II · Moderate risk

Mic Plus B12

Lack of Assurance of Sterility: Lack of sterility assurance in compounded aseptically filled injectable products.

Terminated Sterility / contamination John W Hollis Inc D-1393-2014
Class II · Moderate risk

Bystolic (nebivolol)

Failed Dissolution Specifications: One lot of product is being voluntarily recalled because dissolution test results failed to meet specification throughout the product's shelf life.

Terminated Dissolution failure Forest Pharmaceuticals Inc NDC 0456-1420-30 D-1348-2014
Class I · High risk

African Black Ant

Marketed Without an Approved NDA/ANDA: Eugene FDA laboratory analyses determined they contain undeclared sildenafil.

Terminated Chemical / undeclared Eugene Oregon, Inc. D1612-2014
Class I · High risk

Mojo Risen

Marketed Without an Approved NDA/ANDA: Eugene FDA laboratory analyses determined they contain undeclared sildenafil.

Terminated Chemical / undeclared Eugene Oregon, Inc. D-1614-2014
Class I · High risk

Black Ant

Marketed Without an Approved NDA/ANDA: Eugene FDA laboratory analyses determined they contain undeclared sildenafil.

Terminated Chemical / undeclared Eugene Oregon, Inc. D-1613-2014
Class II · Moderate risk

Hemo-Stat Solution

Marketed without an Approved NDA/ANDA; product is being manufactured and distributed without a NDC number

Terminated Unapproved drug Axcentria Pharmaceuticals, LLC D-1434-2014

Recalls by year